By Conjoint Professor David goldstein

Journal articles

Goldstein D; Sze M; Bell M; King M; Jefford M; Eisenbruch M; Girgis A; Vaccaro L; Butow PN, 2012, 'Disparities in quality-of-life outcomes in immigrant cancer patients.', Journal of Clinical Oncology, 30, pp. e16507 - e16507, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e16507

Chua YJ; Karapetis CS; Underhill C; Nott LM; Goldstein D; Cronk MF; Gebski V; Wong N; Sjoquist KM; Biankin AV, 2012, 'PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer.', Journal of Clinical Oncology, 30, pp. TPS4137 - TPS4137, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps4137

Bennett BK; Lloyd AR; Webber K; Friedlander M; Goldstein D, 2012, 'Predictors of resilience in women treated for breast cancer: A prospective study.', Journal of Clinical Oncology, 30, pp. 9044 - 9044, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9044

Kiely BE; Martin AJ; Tattersall MHN; Nowak AK; Goldstein D; Wilcken N; Wyld D; Beale PJ; Jefford M; Glasgow AL; Abdi EA; Glare PA; Stockler MR, 2012, 'Usefulness of medical oncologists’ estimates of survival time in people with advanced cancer.', Journal of Clinical Oncology, 30, pp. 9087 - 9087, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9087

Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I; Romedi M; Ferrandini S; Rondinon M; Pittman K; Goldstein D; Shapiro J; Troon S; Yip D; Mainwaring P; Zigeuner R; Loidl W; Greil RF; Schmidinger M; De Grève J; Rottey S; Vermorken J; Gil T; Gennigens C; Roumeguere T; Barrios C; Mathias C; Assi H; Hotte S; Karakiewicz P; Knox J; Spadafora S; Wood L; Zalewski P; Mackensie M; Bjarnason G; Lalancette A; Chan A; Higgins B; North S; Soulieres D; Asselah J; Sperlich C; Miller W; Yadav S; El-Maraghi R; Godoy J; Prausová J; Katolicka J; Petruzelka L; Kiss I; Lapela M; Miller K; Bergmann L; Beck J; Jäger E; Kindler M; Overkamp F; Wirth M; Hölzer W; Gschwend J; Stenzl A; Gauler T; Niederwieser D; Marschner N; Lück A; Tessen H; Eichelberg C; Steiner T; Goebell P; Kettner E; Bakhshandeh-Bath A; Wilhelm M; Schmitz S; Jacob A; Bierer S; Kube U; Staehler M; Engel E; Frambach M; Schellenberger U; Albers P; Simon J; Gleissler M; Klotz T; Repp R, 2012, 'An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy', European Journal of Cancer, 48, pp. 324 - 332, http://dx.doi.org/10.1016/j.ejca.2011.06.054

Clarke SJ; Yip S; Brown C; Van Hazel GA; Ransom DT; Goldstein D; Mark Jeffrey G; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; John Simes R, 2012, 'Erratum: Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; Results of a randomised phase II study (DaVINCI) and meta-analysis (European Journal of Cancer (2011) 47:12 (1826-1836))', European Journal of Cancer, 48, pp. 407, http://dx.doi.org/10.1016/j.ejca.2011.12.001

Butow P; Lobb EA; Jefford M; Goldstein D; Eisenbruch M; Girgis A; King MT; Sze M; Aldridge L; Schofield P, 2012, 'A bridge between cultures: Interpreters' perspectives of consultations with migrant oncology patients', Supportive Care in Cancer, 20, pp. 235 - 244, http://dx.doi.org/10.1007/s00520-010-1046-z

Dumont AG; Rink L; Godwin AK; Miettinen M; Joensuu H; Strosberg JR; Gronchi A; Corless CL; Goldstein D; Rubin BP; Maki RG; Lazar AJ; Lev D; Trent JC; von Mehren M, 2012, 'A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.', Annals of Oncology, 23, pp. 1335 - 1340, http://dx.doi.org/10.1093/annonc/mdr442

Goldstein D; Bennett BK; Webber K; Boyle F; De Souza P; Wilcken NRC; Scott E; Toppler R; Murie P; O''Malley L; Mccourt J; Friedlander M; Hickie IB; Lloyd AR, 2012, 'Cancer-related fatigue in women with breast cancer: outcomes of a 5 year prospective cohort study.', Journal of Clinical Oncology, 30, pp. 1805 - 1812, http://dx.doi.org/10.1200/JCO.2011.34.6148

Demetri GD; Garrett C; Sch offski P; Shah M; Verweij J; Leyvraz S; Hurwitz HI; Lopez Pousa A; Le Cesne A; Goldstein D; Paz-Ares L; Blay J; McArthur G; Xu Q; Huang X; Harmon CS; Tassell V; Cohen DP; Casali P, 2012, 'Complete Longitudinal Analyses of the Randomized,Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure', Clinical Cancer Research, 18, pp. 3170 - 3179

Bennett BK; Park SB; Lin CS-Y; Friedlander M; Kiernan MC; Goldstein D, 2012, 'Impact of Oxaliplatin-induced Neuropathy: A Patient Perspective', Supportive Care in Cancer, 20, pp. 2959 - 2967, http://dx.doi.org/10.1007/s00520-012-1428-5

Cameron BA; Bennett B; Li H; Boyle F; deSouza P; Wilcken N; Friedlander M; Goldstein D; Lloyd AR, 2012, 'Post-cancer fatigue is not associated with immune activation or altered cytokine production', Annals of Oncology, 23, pp. 2890 - 2895, http://dx.doi.org/10.1093/annonc/mds108

Mitchison D; Butow PN; Sze M; Aldridge L; Hui R; Vardy JL; Eisenbruch M; Iedema R; Goldstein D, 2012, 'Prognostic Communication Preferences of Migrant Patients and their Relatives', Psycho-oncology, 21, pp. 496 - 504, http://dx.doi.org/10.1002/pon.1923

Butow PN; Philips F; Schweder J; White K; Underhill C; Goldstein D, 2012, 'Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review', Supportive Care in Cancer, 20, pp. 1 - 22

Ngan SY; Burmeister B; Fisher R; Solomon M; Goldstein D; Joseph D; Ackland S; Schache D; McClure B; McLachlan S; McKendrick J; Leong T; Hartopeanu C; Zalcberg J; Mackay J, 2012, 'Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04', Journal of Clinical Oncology, 30, pp. 3827 - 3833

Wang X; Crowe PJ; Goldstein D; Yang JL, 2012, 'STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers', International Journal of Oncology, 41, pp. 1181 - 1191, http://dx.doi.org/10.3892/ijo.2012.1568

Goldstein D; Spry N; Cummins MM; Brown C; Van Hazel GA; Carroll SL; Selva Nayagam S; Borg M; Ackland S; Wratten C; Shapiro J; Porter L; Hruby G; Horvath LG; Bydder S; Underhill C; Harvey JE; Gebski V, 2012, 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106, pp. 61 - 69, http://dx.doi.org/10.1038/bjc.2011.526

Luckett T; Goldstein D; Butow PN; Gebski V; Aldridge LJ; McGrane J; Ng W; King MT, 2011, 'Psychological morbidity and quality of life of ethnic minority patients with cancer: A systematic review and meta-analysis', Lancet Oncology, 12, pp. 1240 - 1248, http://dx.doi.org/10.1016/S1470-2045(11)70212-1

Peng J; Shi D; Goodman KA; Goldstein D; Xiao C; Guan Z; Cai S, 2011, 'Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29', Radiation Oncology, 6, pp. 93, http://dx.doi.org/10.1186/1748-717X-6-93

Butow PN; Goldstein D; Bell ML; Sze M; Aldridge LJ; Abdo S; Tanious M; Dong S; Iedema R; Vardy J; Ashgari R; Hui R; Eisenbruch M, 2011, 'Interpretation in consultations with immigrant patients with cancer: How accurate is it?', Journal of Clinical Oncology, 29, pp. 2801 - 2807, http://dx.doi.org/10.1200/JCO.2010.34.3335

Webber K; Mok K; Bennett BK; Juraskova I; Goldstein D; Friedlander M; Lloyd AR; FOLCAN study group , 2011, 'Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link?', J Clin Oncol, 29, pp. 9072, http://www.ncbi.nlm.nih.gov/pubmed/28021533

Hammel P; Huguet F; Van Laethem J; Goldstein D; Glimelius B; Moore MJ; Chibaudel B; Bonnetain F; Louvet C; Glimelius , 2011, 'Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study.', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.e14619

Goldstein D; Lee C; Tracey E; Cook-Yarborough C; Lord S, 2011, 'Validating innovation: A population-based study of gastrointestinal stromal tumors (GIST) to estimate the survival benefit of imatinib.', J Clin Oncol, 29, pp. 10060, http://www.ncbi.nlm.nih.gov/pubmed/28021288

Arun SJ; Xu Z; Fiala-Beer E; Phillips P; Goldstein D; Biankin A; Pirola R; Wilson JS; Apte MV, 2011, 'Hepatocyte growth factor: a potential therapeutic target in pancreatic cancer', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-LB-395

Yang JL; DasGupta R; Hopkins A; Luk F; Goldstein D; Crowe P, 2011, 'Significance of IGF-1R and Its signaling pathways in human sarcoma', CANCER RESEARCH, 71, http://dx.doi.org/10.1158/1538-7445.AM2011-4416

Goldstein D; Gainford MC; Brown C; Tebbutt N; Ackland SP; Van Hazel G; Jefford M; Abdi E; Selva-Nayagam S; Gebski V; Miller D; Shannon J, 2011, 'Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 67, pp. 519 - 525, http://dx.doi.org/10.1007/s00280-010-1351-8

Clarke SJ; Yip S; Brown C; Van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ, 2011, 'Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; Results of a randomised phase II study (DaVINCI) and meta-analysis', European Journal of Cancer, 47, pp. 1826 - 1836, http://dx.doi.org/10.1016/j.ejca.2011.04.024

Zhi J; Major P; Chen E; Burns I; Robinson B; McKendrick J; Rittweger K; Abt M; Goldstein D, 2011, 'A multi-centre, randomised, open-lable study to assess the steady state paramacokinetics of Bevacizumab given with either Xeloda or FOLFOX-4 in patient with metastatic colorectal cancer', Cancer Chemotherapy and Pharmacology, 68, pp. 1199 - 1206

Sjoquist KM; Goldstein D; Bester L; Bester L, 2011, 'A serious complication of selected internal radiation therapy: case report and literature review', Oncologist, 15, pp. 830 - 835

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Dose effects of Oxaliplatin on persistent and transient na+ conductances and the development of neurotoxicity', PLoS One, 6, pp. 1 - 7, http://dx.doi.org/10.1371/journal.pone.0018469

Goldstein D; Gainford M; Brown C; Tebbutt N; Ackland S; Van Hazel GA; Jefford M; Abdi E; Gebski V; Miller D; Shannon JF, 2011, 'Fixed dose rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas', Cancer Chemotherapy and Pharmacology, 16, pp. 519 - 519

Goldstein D; Butow P; Sze M; Mikhail M; Eisenbruch M, 2011, 'Grappling with cultural differences; Communication between oncologists and immigrant cancer patients with and without interpreters', Patient Education and Counseling, 84, pp. 398 - 405

Webber K; Mok K; Bennett BK; Lloyd AR; Friedlander M; Juraskova I; Goldstein D, 2011, 'If I Am in the Mood, I Enjoy It: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer', Oncologist, 16, pp. 1333 - 1344

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Long-term neuropathy after Oxaliplatin treatment: Challenging the dictum of reversibility', Oncologist, 16, pp. 708 - 716, http://dx.doi.org/10.1634/theoncologist.2010-0248

Webber K; Cooper A; Kleiven H; Yip D; Goldstein D, 2011, 'Management of metastatic renal cell carcinoma in the era of targeted therapies', Internal Medicine Journal, 41, pp. 594 - 605

Park SB; Goldstein D; Lin CS-Y; Krishnan AV; Friedlander M; Kiernan MC, 2011, 'Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?', Journal of clinical oncology - official journal of the American Society of Clinical Oncology, 29, pp. e553 - e554e

Luckett T; Goldstein D; Butow PN; Gebski V; Aldridge L; McGrane J; Ng W; King MT, 2011, 'Psychological morbidity and quality of life of ethnic minority patients with cancer: a systematic review and meta-analysis', Lancet Oncology, 12, pp. 1240 - 1248, http://dx.doi.org/10.1016/S1470

Wirth A; Grigg A; Wolf M; Goldstein D; Johnson C; Davis S; Dutu G; Kypreos P; Smith C; Kneebone A; Herzberg M; Joseph D; Catalano J; Roos DE; Stone J; Reynolds J, 2011, 'Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group', Leukemia and Lymphoma, 52, pp. 786 - 795, http://dx.doi.org/10.3109/10428194.2010.547155

Tebbutt N; murphy F; Zannino D; Wilson D; Cummins MM; Abdi E; Strickland A; Lowenthal RM; Marx G; Karapetis C; Shannon JF; Goldstein D; Nayagam SS; Blum R; Chantrill L; Simes RJ; Price T, 2011, 'Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab', Annals of Oncology, 22, pp. 1834 - 1838

Leighl N; Shepherd H; Butow PN; clarke SJ; Mcjannett M; Beale P; Wilken N; Moore M; Chen E; Goldstein D; Horvath LG; Knox J; Krzyzanowska M; Oza AM; Feld R; Hedley D; Xu W; Tattersall MH, 2011, 'Supporting treatment decision-making in advanced cancer: a randomized trial of a decision aid for patients considering chemotherapy in advanced colorectal cancer', Journal of Clinical Oncology, 29, pp. 2077 - 2084, http://dx.doi.org/10.1200/JCO.2010.32.0754

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander M; Kiernan MC, 2011, 'Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy', Experimental Neurology, 227, pp. 120 - 127, http://dx.doi.org/10.1016/j.expneurol.2010.10.002

Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; Van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ; Coates A; O'Connell D; Brown C; Hague W; France A; Hicks S; James R; Masson R; O'Connell R; Pike R; Shoulder J; Stevens L; Tunney V; Vachan B; Wong N; Ackland S; Moylan E; Strickland A; Abdi E; Ransom D; Lowenthal R; Marx G; Nayagam SS; Shannon J; Goldstein D; Karapetis C; Blum R; Eek R; Ward R; Pavlakis N; Wilcken N; Burns I; Wyld D; Underhill C; Claringbold P; Liauw W; Clingan P; Jefford M; Horvath L; McKendrick J; Chong G; Boyce A; Cassidy J; Kirsten F; Clarke S; Guo Y; Innes-Rowe J; Smith A; Williams J; Tournier E; Maliepaard S; Vitullo E; Humm G; Nguyen V; Midolo P; Chorlton C; McDonald L; Oliver L; Sjursen AM; Inglis C; Marafioti T; McCourt J; Howard J; Richards A; Provis A; Rundle A; Whatman A; Emmett L; Raymond B; Byrne S; Withers E; Campbell J; Hodgkins C; Szwajcer M; Parker S; Welby S; Page F; Corker M; Wykes R; Goss C; Whitney S; Oates J, 2010, 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study', Journal of Clinical Oncology, 28, pp. 3191 - 3198, http://dx.doi.org/10.1200/JCO.2009.27.7723

Ngan S; Fisher R; Goldstein D; Solomon M; Burmeister B; Ackland SP; Joseph DJ; McClure B; McLachlan S; Mackay J, 2010, 'A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS)', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3509

Webber K; Goldstein D; Bennett BK; Boyle FM; De Souza PL; Wilcken N; Friedlander M; Lloyd AR, 2010, 'Influence of fatigue after breast cancer adjuvant theraphy on health care utilization and percieved needs', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.9047

Tebbutt NC; Kotasek D; Burris HA; Schwartzberg LS; Hurwitz H; Stephenson J; Adewoye H; Sun Y; Ye Y; Goldstein D, 2010, 'Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3538

Klumpen H; Eechoute K; Hertzberg MS; Schwarer AA; Goldstein D; Hughes TP; Liddle C; Mathijssen R; Schellens JH; Gurney H, 2010, 'Pharmacogenetic factors predicting the need for a higher dose of imatinib', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.3098

Chua YJ; Michael M; Zalcberg JR; Hicks RJ; Goldstein D; Liauw W; Price T, 2010, 'Antitumor effect of somatostatin analogs in neuroendocrine tumors', Journal of Clinical Oncology, 28, pp. e41 - e42, http://dx.doi.org/10.1200/JCO.2009.26.0612

Lovell MR; Forder PM; Stockler MR; Butow P; Briganti EM; Chye R; Goldstein D; Boyle FM, 2010, 'A randomized controlled trial of a standardized educational intervention for patients with cancer pain', Journal of Pain and Symptom Management, 40, pp. 49 - 59, http://dx.doi.org/10.1016/j.jpainsymman.2009.12.013

Park SB; Lin CS-Y; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2010, '5. A novel biomarker of axonal dysfunction in oxaliplatin-induced neurotoxicity', Clinical Neurophysiology, 121, pp. e2 - e2, http://dx.doi.org/10.1016/j.clinph.2009.10.025

Goldstein D; Butow PN; Boyle F; Stockler M; Lovell M; Chye R; Forder P; Briganti E, 2010, 'A randomized controlled trial of a standardized educational intervention for patients with cancer pain', Journal of Pain and Symptom Management, 49, pp. 49 - 59

Back to profile page